Tumors were evaluated for pharmacokinetics, pharmacodynamics, and single nucleus transcriptomics.<h4>Results</h4>Median unbound ribociclib concentrations in gadolinium non-enhancing tumor regions were significantly above the biochemical IC50 for CDK4/6 inhibition at 400 and 600 mg QD doses. The gene discussed is CDK4; the disease is neoplasm.